Certainly no information to understand the prospects of the business:
- how much will the revenue and cost base change with the sale of the portion of the Condat business? You can't even pick out the German segment in the segment note because as far as I can make out, not all of it has been sold
- what's the cost base of the business going forward? And the revenue model? Lot's of announcements about new contract wins with blue chip names but no way of understanding their impact on the financials.
- what is the Sprooki business now contributing? There was a revenue number but nothing about the operating costs?
As far as I can make out this remains un-modellable, which given the going concern qualification in the audit report, means I can't see whether after they receive the Condat sales proceeds and receive cash for converted notes, will they have to raise cash again in the near future and how much.
IVO Price at posting:
0.7¢ Sentiment: None Disclosure: Not Held
